Aarti Pharmalabs (NSE:AARTIPHARM) Other Current Payables: ₹0 Mil (As of Mar. 2026)


NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
50 GF Score
Price ₹702.95
GF Value ₹642.77
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Other Current Payables?

Aarti Pharmalabs NSE:AARTIPHARM +2.43% 50 Other Current Payables is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 50/100 and a GF Value™ of ₹642.77 (Fairly Valued). The stock has 3 warning signs investors should review.

Aarti Pharmalabs's Other Current Payables for the quarter that ended in Mar. 2026 was ₹0 Mil.

Aarti Pharmalabs's annual Other Current Payables increased from Mar. 2024 (₹154 Mil) to Mar. 2025 (₹203 Mil) but then declined from Mar. 2025 (₹203 Mil) to Mar. 2026 (₹0 Mil).

Aarti Pharmalabs Other Current Payables Related Terms

Aarti Pharmalabs Other Current Payables Historical Data

* Premium members only.

The historical data trend for Aarti Pharmalabs's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Pharmalabs Other Current Payables Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial 0.00 211.15 154.00 202.95 0.00

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 202.95 0.00 0.00 0.00 0.00
NSE:AARTIPHARM
50GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Pharmalabs Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ₹0 Mil mean?
Aarti Pharmalabs (NSE:AARTIPHARM) has a Other Current Payables of ₹0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Aarti Pharmalabs and its competitors.
Is Aarti Pharmalabs' Other Current Payables too high?
Aarti Pharmalabs' current Other Current Payables is ₹0 Mil. Overall, Aarti Pharmalabs has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Other Current Payables compare to ZTS and UTHR?
Aarti Pharmalabs' Other Current Payables of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Aarti Pharmalabs and its competitors. Aarti Pharmalabs's current Other Current Payables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹642.77, compared to a current price of ₹702.95 — trading 9.4% above its estimated fair value. The current Other Current Payables is ₹0 Mil. Aarti Pharmalabs' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current Other Current Payables is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹702.95 is trading 9.4% above its estimated GF Value™ of ₹642.77. GuruFocus considers Aarti Pharmalabs to be Fairly Valued.

Key valuation signals for NSE:AARTIPHARM:

  • Other Current Payables: ₹0 Mil
  • GF Value™: ₹642.77 vs. price of ₹702.95 (9.4% above fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
50GF Score

Get the complete analysis for NSE:AARTIPHARM

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹702.95
Price
₹642.77
GF Value